false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - The Car ...
Cardiovascular Disease in the CKM Framework: What ...
Cardiovascular Disease in the CKM Framework: What Nephrology Clinicians Need to Test, Treat, and Refer
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Ian Neeland explains how nephrologists can help prevent cardiovascular disease in patients with chronic kidney disease (CKD), working alongside cardiologists. Because cardiovascular and kidney disease share metabolic, hemodynamic, inflammatory, and fibrotic pathways, care should assess and address both.<br /><br />He recommends routine CKM staging and annual review of cardiovascular risk factors in most CKD patients, including blood pressure, BMI, waist circumference, lipids, glycemia, and kidney function. The PREVENT equations can estimate cardiovascular risk, including heart failure risk, and help guide treatment. Risk enhancers—such as urine albumin-to-creatinine ratio, coronary calcium, lipoprotein(a), and inflammation markers—can further inform decisions.<br /><br />Treatment should be personalized to risk, prioritize therapies with proven outcome benefits, and combine complementary approaches when appropriate. Foundational options include renin–angiotensin system blockade, SGLT2 inhibitors, and statins; GLP-1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists may be added based on a patient’s conditions and residual risk. High-risk patients may warrant faster treatment sequencing, with regular reassessment of effectiveness, side effects, affordability, and adherence.<br /><br />Nephrologists can initiate appropriate cardiovascular risk-reduction therapies rather than waiting for specialist review. Referral to cardiology is especially appropriate for patients with advanced CKM stages, high predicted cardiovascular or heart failure risk, or multiple risk enhancers.
Asset Caption
Ian J. Neeland, MD
Meta Tag
Speaker
Ian J. Neeland
Keywords
chronic kidney disease
cardiovascular disease
CKM staging
PREVENT equations
SGLT2 inhibitors
statins
cardiology referral
×
Please select your language
1
English